アブストラクト
Japanese
| Title | 2型糖尿病合併心不全患者におけるSGLT2阻害薬の有益な効果 |
|---|---|
| Subtitle | ケースレポート |
| Authors | 中嶋丈晴 |
| Authors (kana) | |
| Organization | 東北労災病院 薬剤部 |
| Journal | 医薬品相互作用研究 |
| Volume | 44 |
| Number | 2 |
| Page | 107-112 |
| Year/Month | 2020 / |
| Article | 報告 |
| Publisher | 医薬品相互作用研究会 |
| Abstract | 「諸言」 日本において, ナトリウム・グルコース共輸送体(Sodium glucose co-transporter 2 : SGLT2)阻害薬は2014年4月にイプラグリフロジンが発売されて以来, 現在までに6つの成分が発売されている. これまでの糖尿病治療薬とは異なる新規作用機序を持つ糖尿病治療薬である. SGLT2は腎臓の近位曲尿細管に存在しており, ナトリウムとグルコースを共輸送する機能を有している. SGLT2によって, 原尿に含まれる約90%のグルコースが再吸収されている. 残りの約10%のグルコースは, 近位直尿細管に存在するSGLT1によって再吸収されるため, 通常尿糖排泄はほとんど認められない. SGLT2阻害薬は, 腎臓の近位尿細管に発現するSGLT2に作用して, グルコースの再吸収を阻害し, 尿糖排泄を促進することにより, 血糖降下作用を示すことが報告されている. SGLT2阻害薬の効能・効果は糖尿病のみであるが, いくつかの臨床試験において, 心不全による入院の抑制, 心血管死の減少などが報告されている. |
| Practice | 薬学 |
| Keywords | SGLT2 inhibitors, heart failure, diabetes, diuretics, urine volume |
English
| Title | Beneficial effects of SGLT2 inhibitors in heart failure patients with type 2 diabetes. |
|---|---|
| Subtitle | |
| Authors | Takeharu NAKAJIMA |
| Authors (kana) | |
| Organization | Department of Pharmacy, Tohoku Rosai Hospital |
| Journal | Journal of Drug Interaction Research |
| Volume | 44 |
| Number | 2 |
| Page | 107-112 |
| Year/Month | 2020 / |
| Article | Report |
| Publisher | Research On Drug Interactions |
| Abstract | Recent studies have shown that SGLT2 inhibitors, routinely used in type 2 diabetes, reduce cardiovascular-related death and hospitalization in heart failure patients. We report a case study showing the effective treatment of a patient with heart failure using SGLT2 inhibitors. The patient was a 77-year-old man hospitalized for chronic heart failure exacerbation. After hospitalization, the patient was administered carperitide and furosemide injections. As his condition improved, the treatment was switched to a combination of oral diuretics such as torasemide, azosemide, and tolvaptan. Despite the combined use of multiple oral diuretics, the patient still presented with edema and increased preload. At this point, additional empagliflozin was administered to the patient, and an increase in urine volume and weight loss were observed. No adverse reactions were observed such as electrolyte abnormality, dehydration, and urinary tract infection. We propose that the administration of SGLT2 inhibitors to heart failure patients with type 2 diabetes may aid in treating heart failure. |
| Practice | Pharmaceutical sciences |
| Keywords | SGLT2 inhibitors, heart failure, diabetes, diuretics, urine volume |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Chao EC, Henry RR: SGLT2 inhibition a novel strategy for diabetes treatment., Nat Rev Drug Discov., 9(7), 551-9, 2010
- 2) Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME(R) trial investigators: Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial., Eur Heart J., 37(19), 1526-34, 2016
- 3) Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group: Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes., N Engl J Med., 377(7), 644-657, 2017
- 4) Heise T, Jordan J, Wanner C, Heer M, Macha S, Mattheus M, Lund SS, Woerle HJ, Broedl UC: Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes., Clin Ther., 38(10), 2265-2276, 2016
- 5) Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M: Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus., Clin Pharmacol Ther., 85(5), 513-9, 2009
残りの12件を表示する
- 6) Tanaka H, Takano K, Iijima H, Kubo H, Maruyama N, Hashimoto T, Arakawa K, Togo M, Inagaki N, Kaku K: Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus., Adv Ther., 34(2), 436-451, 2017
- 7) Eickhoff MK, Dekkers CCJ, Kramers BJ, Laverman GD, Frimodt-Moller M, Jorgensen NR, Faber J, Danser AHJ, Gansevoort RT, Rossing P, Persson F, Heerspink HJL: Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors., J Clin Med., 8(6), 779-790, 2019
- 8) 日本循環器学会,日本心不全学会:日本循環器学会/日本心不全学会合同ガイドライン, 急性・慢性心不全診療ガイドライン(2017年改訂版)
- 9) Eshaghian S, Horwich TB, Fonarow GC: Relation of loop diuretic dose to mortality in advanced heart failure., Am J Cardiol., 97(12), 1759-64, 2006
- 10) Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT: BG9719(CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy., Circulation., 105(11), 1348-53, 2002
- 11) Inomata T, Ikeda Y, Kida K, Shibagaki Y, Sato N, Kumagai Y, Shinagawa H, Ako J, Izumi T; Kanagawa Aquaresis Investigators: Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment - Results From the K-STAR Study., Circ J., 82(1), 159-167, 2017
- 12) Kambara T, Shibata R, Osanai H, Nakashima Y, Asano H, Murohara T, Ajioka M: Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure., Ther Adv Cardiovasc Dis., 13, 1-10, 2019
- 13) Ohara K, Masuda T, Murakami T, Imai T, Yoshizawa H, Nakagawa S, Okada M, Miki A, Myoga A, Sugase T, Sekiguchi C, Miyazawa Y, Maeshima A, Akimoto T, Saito O, Muto S, Nagata D: Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan., Nephrology., 24(9), 904-911, 2019
- 14) Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW: Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis., Diabetes Obes Metab., 20(3), 479-487, 2018
- 15) 日本糖尿病学会:SGLT2阻害薬の適正使用に関する委員会:SGLT2阻害薬の適正使用に関するRecommendation
- 16) Takeuchi T, Dohi K, Omori T, Moriwaki K, Sato Y, Nakamori S, Fujimoto N, Fujii E, Yamada N, Ito M: Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure., Int J Cardiol., 201, 1-3, 2015
- 17) Sano M: A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity., J Cardiol., 71(5), 471-476, 2018
